Editorial for “Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima”
Journal of Magnetic Resonance Imaging · 2023
DOI: 10.1002/jmri.28646 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Magnetic Resonance Imaging, 2023. Verfasst von Paul Nyquist. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Diaschisis, Cerebellar Diseases. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Department of Anesthesia/Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Department of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Paul Nyquist
Zitieren
APA
Nyquist, P. (2023). Editorial for “Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima”. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.28646
Vancouver
Nyquist P. Editorial for “Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima”. Journal of Magnetic Resonance Imaging. 2023. doi:10.1002/jmri.28646
BibTeX
@article{Nyquist2023,
author = {Nyquist, Paul},
title = {Editorial for “Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima”},
journal = {Journal of Magnetic Resonance Imaging},
year = {2023},
doi = {10.1002/jmri.28646}
}
EUVIMED